Profil
Joong-Ki Baik worked as a Director at Venturis Therapeutics, Inc. from 2005 to 2014.
Prior to that, he was an Executive Director in the Economic Research Department at The Korea Chamber of Commerce & Industry from 1978 to 2000.
Baik graduated from The University of York with a graduate degree and from Yonsei University with an undergraduate degree.
Anciens postes connus de Joong-Ki Baik
| Sociétés | Poste | Fin |
|---|---|---|
Venturis Therapeutics, Inc.
 Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Directeur/Membre du Conseil | 16/09/2014 |
The Korea Chamber of Commerce & Industry
 The Korea Chamber of Commerce & Industry Miscellaneous Commercial ServicesCommercial Services The Korea Chamber of Commerce & Industry (KCCI) is a business organization that provides resources, publications, events, and networks for its members. The organization is based in Seoul, North Korea and has overseas offices. The KCCI advocates for its members and partners with other organizations to promote bilateral economic cooperation. The KCCI also provides economic data and policy issues publications and hosts business forums and roundtables. Recently, the KCCI hosted a successful business forum with over 600 attendees, including political and business leaders from both countries. The Financial Services Commission identified five bank holding companies and five banks as domestic systemically important banks for 2024, and those identified as D-SIBs are required to set aside an additional common equity capital of 1.0, and the higher loss absorbency requirement will take effect on January 1, 2024. | Corporate Officer/Principal | 01/07/2000 |
Formation de Joong-Ki Baik
| Yonsei University | Undergraduate Degree |
| The University of York | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
The Korea Chamber of Commerce & Industry
The Korea Chamber of Commerce & Industry Miscellaneous Commercial ServicesCommercial Services The Korea Chamber of Commerce & Industry (KCCI) is a business organization that provides resources, publications, events, and networks for its members. The organization is based in Seoul, North Korea and has overseas offices. The KCCI advocates for its members and partners with other organizations to promote bilateral economic cooperation. The KCCI also provides economic data and policy issues publications and hosts business forums and roundtables. Recently, the KCCI hosted a successful business forum with over 600 attendees, including political and business leaders from both countries. The Financial Services Commission identified five bank holding companies and five banks as domestic systemically important banks for 2024, and those identified as D-SIBs are required to set aside an additional common equity capital of 1.0, and the higher loss absorbency requirement will take effect on January 1, 2024. | Commercial Services |
